Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).

Ibrutinib, the first-in-class oral Bruton tyrosine kinase (BTK) inhibitor, is a highly effective therapy for both naive or relapsed/refractory chronic lymphocytic leukemia (CLL) patients [1]. The t...